Merck Serono
Diatech Pharmacogenetics, Merck KGaA Expand RAS Biomarker Testing Pact in Middle East, Africa
The companies are collaborating to improve access to biomarker testing to inform the use of targeted therapies in colorectal cancer across the region.
Nonprofit Friends of Cancer Research Launches Public-Private HRD Harmonization Project
The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.
FDA Gives Guardant Health IDE Approval for Clinical Trial of Merck KGaA Cancer Drug
Guardant is providing its Guardant 360 CDx test for a clinical trial of Merck's small molecule, c-Met kinase inhibitor called tepotinib.
Illumina, Merck Serono to Develop Universal NGS-based Oncology Dx
The collaboration adds to a similar agreement Illumina struck with AstraZeneca, Janssen Biotech, and Sanofi last year.
Spanish Cancer Institute Using Sysmex Inostics, Merck Serono Blood Dx to Study mCRC Personalized Rx
Premium
Vall d'Hebron's Institute of Oncology will use the liquid biopsy-based OncoBEAM RAS test to research precision medicine approaches for metastatic colorectal cancer patients.
Sep 3, 2012
Merck Serono Spins Out Bioinformatics Firm
Jun 25, 2012
Merck Serono, Compugen Form Biomarker Discovery Firm
Jun 10, 2009
BioSeek Extends Merck Profiling Plan to 2012
Mar 30, 2009
Mar 25, 2009